- Home
- COLL
as 04-01-2025 4:00pm EST
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | STOUGHTON |
| Market Cap: | 910.2M | IPO Year: | 2015 |
| Target Price: | $43.60 | AVG Volume (30 days): | 443.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.86 | EPS Growth: | 43.56 |
| 52 Week Low/High: | $27.28 - $42.29 | Next Earning Date: | 05-08-2025 |
| Revenue: | $631,449,000 | Revenue Growth: | 11.41% |
| Revenue Growth (this year): | 20% | Revenue Growth (next year): | 3.93% |
Stock Insider Trading Activity of Collegium Pharmaceutical Inc. (COLL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 20 '25 | Sell | $30.01 | 20,808 | $624,794.18 | 103,613 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 14 '25 | Sell | $30.00 | 2,255 | $67,661.05 | 103,613 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Mar 14 '25 | Sell | $30.00 | 977 | $29,313.32 | 164,269 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 11 '25 | Sell | $30.00 | 30,774 | $923,343.10 | 103,613 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Mar 11 '25 | Sell | $30.01 | 10,445 | $313,412.67 | 164,269 | |
| Dreyer Scott | COLL | EVP & Chief Commercial Officer | Mar 6 '25 | Sell | $30.00 | 5,643 | $169,299.49 | 103,613 | |
| Tupper Colleen | COLL | EVP & Chief Financial Officer | Mar 6 '25 | Sell | $30.00 | 3,453 | $103,591.05 | 164,269 | |
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Mar 4 '25 | Sell | $28.20 | 86,067 | $2,426,633.99 | 108,137 | |
| Kuhlmann Shirley R. | COLL | EVP and General Counsel | Jan 10 '25 | Sell | $33.26 | 27,500 | $908,627.77 | 108,137 |
Latest Collegium Pharmaceutical Inc. News
COLL Breaking Stock News: Dive into COLL Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 hours ago
Collegium to Participate in 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire
6 days ago
Collegium to Present Real-World Data at PainConnect 2025, the American Academy of Pain Medicine’s Annual Meeting
GlobeNewswire
7 days ago
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
Argus Research
7 days ago
COLL: Raising target price to $32.00
StockStory
12 days ago
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
Investor's Business Daily
14 days ago
Teva Pharmaceutical Stock Scores RS Rating Upgrade
GlobeNewswire
16 days ago
Collegium Announces Updates to its Board of Directors and Executive Leadership Team
MT Newswires
19 days ago
Collegium Pharmaceutical Insider Sold Shares Worth $313,413, According to a Recent SEC Filing
Compare COLL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COLL Collegium Pharmaceutical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.